Modalis Therapeutics, the biotechnology company developing novel gene-based therapies for the rare inherited muscle disease LAMA2-MD, has recently published an…
The Dutch foundation Voor Sara is investing over €45,000 in a promising research project led by Professor Markus Rüegg at…
The French patient association LAMA2 France, dedicated to people affected by LAMA2-related dystrophy (LAMA2-RD), is pleased to announce that they…
Postdoctoral researcher Boris Shneyer shares the latest developments in his research on LAMA2-RD, the progress made so far, and the…
This week marks an important milestone: a scientific publication has been released describing the first steps toward developing a care…
We are excited to share that the Vall d’Hebron Research Institute (VHIR) in Barcelona, Spain, has received funding from the…
